“Interim Analysis of Phase 2 Results for Cemiplimab, a Human Monoclonal Antibody to Programmed Death-1, in Patients with Locally Advanced Cutaneous Squamous Cell Carcinoma”, J of Skin, vol. 2, p. S77, Dec. 2018, doi: 10.25251/skin.2.supp.77.